AR104735A1 - Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2, método de tratamiento, uso - Google Patents
Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2, método de tratamiento, usoInfo
- Publication number
- AR104735A1 AR104735A1 ARP160101500A ARP160101500A AR104735A1 AR 104735 A1 AR104735 A1 AR 104735A1 AR P160101500 A ARP160101500 A AR P160101500A AR P160101500 A ARP160101500 A AR P160101500A AR 104735 A1 AR104735 A1 AR 104735A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- inhibitor
- bcl
- phenyl
- sulfonyl
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title abstract 5
- 229940123711 Bcl2 inhibitor Drugs 0.000 title abstract 5
- 229940083338 MDM2 inhibitor Drugs 0.000 title abstract 5
- 239000012819 MDM2-Inhibitor Substances 0.000 title abstract 5
- 238000002648 combination therapy Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title 1
- -1 4 - {[2- (4-chlorophenyl) -4,4-dimethylcyclohex-1- en-1-yl] methyl} piperazin-1-yl Chemical group 0.000 abstract 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 3
- TVTXCJFHQKSQQM-LJQIRTBHSA-N 4-[[(2r,3s,4r,5s)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC(=O)[C@H]1[C@H](C=2C(=C(Cl)C=CC=2)F)[C@@](C#N)(C=2C(=CC(Cl)=CC=2)F)[C@H](CC(C)(C)C)N1 TVTXCJFHQKSQQM-LJQIRTBHSA-N 0.000 abstract 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 abstract 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 abstract 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 abstract 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 abstract 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 229960003347 obinutuzumab Drugs 0.000 abstract 1
- 229920001542 oligosaccharide Polymers 0.000 abstract 1
- 150000002482 oligosaccharides Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229960004641 rituximab Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 235000000346 sugar Nutrition 0.000 abstract 1
- 150000008163 sugars Chemical class 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Terapia combinada de un anticuerpo anti-CD20 con un inhibidor de Bcl-2 y un inhibidor de MDM2 para el tratamiento del cáncer, especialmente a la terapia combinada de cánceres que expresan CD20 con un anticuerpo anti-CD20 de tipo 1 o un anticuerpo B-Ly1 humanizado no fucosilado y un inhibidor de Bcl-2 y un inhibidor de MDM2. Reivindicación 1: Un anticuerpo anti-CD20 para el tratamiento del cáncer en combinación con un inhibidor de Bcl-2 y un inhibidor de MDM2. Reivindicación 5: El anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 4, caracterizado por que dicho anticuerpo anti-CD20 no fucosilado es un anticuerpo B-Ly1 humanizado. Reivindicación 6: El anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 5, caracterizado por que dicho anticuerpo anti-CD20 no fucosilado es obinutuzumab. Reivindicación 7: El anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 5, caracterizado por que dicho anticuerpo anti-CD20 de tipo I es rituximab. Reivindicación 8: El anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 7, caracterizado por que el inhibidor de Bcl-2 es 4-(4-{[2-(4-clorofenil)-4,4-dimetilciclohex-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirrolo[2,3-b]piridin-5-iloxi)-N-({4-[(tetrahidro-2H-piran-4-ilmetil)amino]-3-[(trifluorometil)sulfonil]fenil}sulfonil)benzamida. Reivindicación 9: El anticuerpo de acuerdo con una cualquiera de las reivindicaciones 1 a 7, caracterizado por que el inhibidor de MDM2 es ácido 4-{[(2R,3S,4R,5S)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxibienzoico. Reivindicación 11: Una composición farmacéutica que comprende una combinación de un anticuerpo anti-CD20 de tipo I o un anticuerpo B-Ly1 humanizado que está sin fucosilar con una cantidad de fucosa del 60% o menos de la cantidad total de oligosacáridos (azúcares) en Asn297, y 4-(4-{[2-(4-clorofenil)-4,4-dimetilciclohex-1-en-1-il]metil}piperazin-1-il)-2-(1H-pirrolo[2,3-b]piridin-5-iloxi)-N-({4-[(tetrahidro-2H-piran-4-ilmetil)amino]-3-[(trifluorometil)sulfonil]fenil}sulfonil)benzamida y ácido 4-{[(2R,3S,4R,5S)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxibenzoico o una sal de los mismos para el tratamiento del cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15169199 | 2015-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR104735A1 true AR104735A1 (es) | 2017-08-09 |
Family
ID=53264535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160101500A AR104735A1 (es) | 2015-05-26 | 2016-05-24 | Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2, método de tratamiento, uso |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20160347852A1 (es) |
| EP (1) | EP3302549B1 (es) |
| JP (1) | JP6612362B2 (es) |
| KR (1) | KR102043803B1 (es) |
| CN (1) | CN107847600B (es) |
| AR (1) | AR104735A1 (es) |
| AU (1) | AU2016267564B2 (es) |
| BR (1) | BR112017023517A2 (es) |
| CA (1) | CA2984706A1 (es) |
| CL (1) | CL2017002983A1 (es) |
| CR (1) | CR20170529A (es) |
| DK (1) | DK3302549T3 (es) |
| ES (1) | ES2744624T3 (es) |
| HK (1) | HK1252855A1 (es) |
| HR (1) | HRP20191585T1 (es) |
| HU (1) | HUE044853T2 (es) |
| IL (1) | IL255353B (es) |
| LT (1) | LT3302549T (es) |
| MA (1) | MA44645B1 (es) |
| MX (1) | MX2017014977A (es) |
| MY (1) | MY188849A (es) |
| NZ (1) | NZ736727A (es) |
| PE (1) | PE20180454A1 (es) |
| PL (1) | PL3302549T3 (es) |
| PT (1) | PT3302549T (es) |
| RS (1) | RS59204B1 (es) |
| RU (1) | RU2727196C2 (es) |
| SI (1) | SI3302549T1 (es) |
| UA (1) | UA124617C2 (es) |
| WO (1) | WO2016188935A1 (es) |
| ZA (1) | ZA201707357B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102158467B1 (ko) | 2012-09-07 | 2020-09-25 | 제넨테크, 인크. | Ｉｉ형 항-ｃｄ20 항체와 선택적 ｂｃｌ-2 억제제와의 병용 치료요법 |
| CN110402097A (zh) | 2016-12-07 | 2019-11-01 | 普罗根尼蒂公司 | 胃肠道检测方法、装置和系统 |
| WO2018183929A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| US20210106703A1 (en) * | 2017-11-22 | 2021-04-15 | Nordic Nanovector Asa | Radioimmunoconjugates in combination with other drugs as treatment against nhl |
| SG11202005784YA (en) | 2018-01-10 | 2020-07-29 | Recurium Ip Holdings Llc | Benzamide compounds |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| CA3092753C (en) * | 2018-07-31 | 2023-10-17 | Ascentage Pharma (Suzhou) Co., Ltd. | Synergistic antitumor effect of bcl-2 inhibitor combined with rituximab |
| EP3672595B1 (en) | 2018-07-31 | 2021-07-21 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| WO2020106754A1 (en) | 2018-11-19 | 2020-05-28 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| EP3870261B1 (en) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090098118A1 (en) * | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| JP2014507384A (ja) * | 2010-12-16 | 2014-03-27 | ロシュ グリクアート アーゲー | Ｍｄｍ２阻害剤とのアフコシル化ｃｄ２０抗体の併用療法 |
-
2016
- 2016-05-23 MY MYPI2017704447A patent/MY188849A/en unknown
- 2016-05-23 HU HUE16725104 patent/HUE044853T2/hu unknown
- 2016-05-23 DK DK16725104.0T patent/DK3302549T3/da active
- 2016-05-23 PT PT16725104T patent/PT3302549T/pt unknown
- 2016-05-23 MA MA44645A patent/MA44645B1/fr unknown
- 2016-05-23 CR CR20170529A patent/CR20170529A/es unknown
- 2016-05-23 KR KR1020177036968A patent/KR102043803B1/ko active IP Right Grant
- 2016-05-23 LT LTEP16725104.0T patent/LT3302549T/lt unknown
- 2016-05-23 AU AU2016267564A patent/AU2016267564B2/en not_active Ceased
- 2016-05-23 WO PCT/EP2016/061517 patent/WO2016188935A1/en active Application Filing
- 2016-05-23 JP JP2017561265A patent/JP6612362B2/ja not_active Expired - Fee Related
- 2016-05-23 ES ES16725104T patent/ES2744624T3/es active Active
- 2016-05-23 PL PL16725104T patent/PL3302549T3/pl unknown
- 2016-05-23 EP EP16725104.0A patent/EP3302549B1/en active Active
- 2016-05-23 RU RU2017145649A patent/RU2727196C2/ru active
- 2016-05-23 PE PE2017002462A patent/PE20180454A1/es unknown
- 2016-05-23 NZ NZ736727A patent/NZ736727A/en not_active IP Right Cessation
- 2016-05-23 BR BR112017023517-0A patent/BR112017023517A2/pt not_active IP Right Cessation
- 2016-05-23 UA UAA201712737A patent/UA124617C2/uk unknown
- 2016-05-23 SI SI201630376T patent/SI3302549T1/sl unknown
- 2016-05-23 MX MX2017014977A patent/MX2017014977A/es unknown
- 2016-05-23 RS RSP20191139 patent/RS59204B1/sr unknown
- 2016-05-23 CA CA2984706A patent/CA2984706A1/en active Pending
- 2016-05-23 CN CN201680043763.1A patent/CN107847600B/zh not_active Expired - Fee Related
- 2016-05-24 AR ARP160101500A patent/AR104735A1/es unknown
- 2016-05-26 US US15/166,149 patent/US20160347852A1/en not_active Abandoned
-
2017
- 2017-10-30 ZA ZA2017/07357A patent/ZA201707357B/en unknown
- 2017-10-31 IL IL255353A patent/IL255353B/en unknown
- 2017-11-24 CL CL2017002983A patent/CL2017002983A1/es unknown
-
2018
- 2018-09-21 HK HK18112186.9A patent/HK1252855A1/zh unknown
-
2019
- 2019-09-03 HR HRP20191585 patent/HRP20191585T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR104735A1 (es) | Terapia combinada de un anticuerpo anti-cd20 con un inhibidor de bcl-2 y un inhibidor de mdm2, método de tratamiento, uso | |
| HUE059624T2 (hu) | N-(fenil)-2-(fenil)pirimidin-4-karboxamid származékok és rokon vegyületek HPK1-inhibitorokként rák kezelésére | |
| CL2020000122A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
| PE20220253A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| BR112013012740A2 (pt) | sais e formas cristalinas de um agente que induz apoptose | |
| MX2021013817A (es) | Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer. | |
| CL2016002970A1 (es) | Sales de adición de (s)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirrolo[1,2-f][1,2,4]triazina-5-carbonitrilo. | |
| BR112015029455A8 (pt) | compostos químicos, uso, métodos e composições para prevenção ou tratamento de câncer | |
| PE20171241A1 (es) | Terapias de combinacion para el tratamiento de canceres | |
| PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| PE20170705A1 (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) | |
| CY1121421T1 (el) | Φαρμακοτεχνικες μορφες | |
| BR112016011065A8 (pt) | composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia | |
| BR112016028749A2 (pt) | composto, forma cristalina, composição farmacêutica, e, método para o tratamento de uma doença. | |
| BR112017004673A2 (pt) | formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida | |
| PE20161236A1 (es) | Compuesto de triazina y su uso para fines medicos | |
| CO2020016582A2 (es) | Sales de sepiapterina farmacéuticamente aceptables | |
| BR112013029999A2 (pt) | derivados de tiazol | |
| BR112018011851A2 (pt) | compostos de isoindol | |
| PE20170148A1 (es) | Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer | |
| CL2015002593A1 (es) | Formas cristalinas de inhibidores de tirosin quinasa y sus sales | |
| CL2019001628A1 (es) | Combinación farmacéutica que comprende un bloqueador del canal de calcio de tipo t. | |
| BR112016017985A2 (pt) | Composição farmacêutica para administração tópica e usos da mesma na fabricação de medicamentos | |
| BR112018012660A2 (pt) | composto, sal, composto sólido, polimorfo a, polimorfo b, polimorfo c, polimorfo d, composição, método de inibição da atividade de gls1 em uma amostra biológica, métodos de tratamento de um distúrbio mediado por gls1 em um sujeito necessitado, composto, sal, solvato ou polimorfo, e uso de um composto, sal, solvato ou polimorfo | |
| RU2017111848A (ru) | Новая фармацевтическая композиция для профилактики и/или лечения недержания мочи |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |